Amphetamine and negative symptoms of schizophrenia

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Psychopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/BF02246180PMID 8741946
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography

  2004cited by this paper
• Partial improvement in negative schizophrenic symptoms after amphetamine

  2004cited by this paper
• Differential effects of amphetamine and neuroleptics on negative Vs. positive symptoms in schizophrenia

  2004cited by this paper
• Acute d-amphetamine challenge in schizophrenia: effects on cerebral glucose utilization and clinical symptomatology.

  1994cited by this paper
• Iron, copper, zinc, magnesium, and calcium in postmortem brain tissue from schizophrenic patients.

  1994cited by this paper
• Negative symptoms and hypofrontality in chronic schizophrenia.

  1992cited by this paper
• Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia.

  1991cited by this paper
• Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia.

  1991cited by this paper
• Dopamine in schizophrenia: a review and reconceptualization.

  1991cited by this paper
• Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients.

  1989cited by this paper
• Implications of normal brain development for the pathogenesis of schizophrenia.

  1988cited by this paper
• Sleepiness and motor vehicle accidents.

  1988cited by this paper
• Dextro-amphetamine diminishes negative symptoms in schizophrenia.

  1988cited by this paper
• Implications of normal brain development for the pathogenesis of schizophrenia.

  1987cited by this paper
• Differential response to amphetamine in schizophrenia

  1985cited by this paper
• Negative symptoms in schizophrenia

  1982cited by this paper
• d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.

  1982influential reference
• Tricyclics versus ECT.

  1978cited by this paper
• A rating scale for emotional blunting.

  1978cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper

• Dopamine partial agonists and prodopaminergic drugs for schizophrenia: systematic review and meta-analysis of randomized controlled trials.

  2022cites this paper
• The monoamine‐oxidase B inhibitor deprenyl increases selection of high‐effort activity in rats tested on a progressive ratio/chow feeding choice procedure: Implications for treating motivational dysfunctions

  2018cites this paper
• Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder

  2018influential citation
• Lipopolysaccharide exposure during late embryogenesis results in diminished locomotor activity and amphetamine response in females and spatial cognition impairment in males in adult, but not adolescent rat offspring.

  2016cites this paper
• The effects in rats of lisdexamfetamine in combination with olanzapine on mesocorticolimbic dopamine efflux, striatal dopamine D2 receptor occupancy and stimulus generalization to a D-amphetamine cue.

  2016cites this paper
• In vitro, molecular modeling and behavioral studies of 3-{[4-(5-methoxy-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl}-1,2-dihydroquinolin-2-one (D2AAK1) as a potential antipsychotic.

  2016cites this paper
• Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?

  2015cites this paper
• Striatal dopamine receptor plasticity in neurotensin deficient mice.

  2015cites this paper
• Bridging immune activation with the kynurenine pathway : implications for psychosis

  2015cites this paper
• Translating the Glutamatergic Hypothesis of Schizophrenia Through Homeostatic Regulation of Brain Glycine

  2015cites this paper
• Safety and Pharmacokinetics of Lisdexamfetamine Dimesylate in Adults With Clinically Stable Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial of Ascending Multiple Doses

  2014cites this paper
• SSR504734 enhances basal expression of prepulse inhibition but exacerbates the disruption of prepulse inhibition by apomorphine

  2013cites this paper
• A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities.

  2013influential citation
• Adenosinergic Perspectives on Schizophrenia: Opportunity for an Integrative Synthesis

  2013cites this paper
• Offenders with Schizophrenia: Relationship to Psychopathology

  2013cites this paper
• Konzeption und Grundlagen einer funktionalen Psycho pharmako therapie

  2012cites this paper
• Management of Schizophrenia in Children and Adolescents

  2011cites this paper
• Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models.

  2011cites this paper
• Influence de la consommation de substances sur l'émergence et l'évolution des troubles psychotiques: le cas du cannabis

  2010cites this paper
• Current pharmacological models of social withdrawal in rats: relevance to schizophrenia

  2010cites this paper
• Neuroadaptations to chronic exposure to drugs of abuse: Relevance to depressive symptomatology seen across psychiatric diagnostic categories

  2009cites this paper
• Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment.

  2009cites this paper
• Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

  2009cites this paper
• Interactions between the glycine transporter 1(GlyT1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour.

  2009cites this paper
• The Relevance of Neuroactive Steroids in Schizophrenia, Depression, and Anxiety Disorders

  2007cites this paper
• Pharmacotherapy of psychotic disorders in children and adolescents

  2006cites this paper
• Recurrence of clozapine-induced agranulocytosis.

  2005cites this paper
• (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia.

  2005cites this paper
• Effective adjunctive use of pergolide with quetiapine for cognitive impairment and negative symptoms in schizophrenia.

  2005cites this paper
• Amphetamines for schizophrenia.

  2004cites this paper
• Stimulant psychosis: systematic review Stimulant psychosis: systematic review

  2004cites this paper
• Stimulant psychosis: systematic review

  2004cites this paper
• Phencyclidine Exacerbates Attentional Deficits in a Neurodevelopmental Rat Model of Schizophrenia

  2003cites this paper
• Sense and non-sense of polypharmacy: increasing efficacy, decreasing compliance?

  2003cites this paper
• The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment

  2003cites this paper
• The prescription of dexamphetamine to patients with schizophrenia and amphetamine dependence

  2002cites this paper
• Genetics and etiopathophysiology of schizophrenia.

  2002cites this paper
• Augmentation Strategies in the Treatment of Schizophrenia

  2001cites this paper
• Progesterone modulation of D5 receptor expression in hypothalamic ANP neurons, the role of estrogen

  2001cites this paper
• Mazindol Treatment of Negative Symptoms

  2000cites this paper
• Glucocorticoid modulation of dopamine mediated effects on hypothalamic atrial natriuretic factor neurons

  2000cites this paper
• Increased dopamine transmission in schizophrenia: relationship to illness phases.

  1999cites this paper
• The ethics of conducting psychosis-inducing experiments.

  1999cites this paper
• Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters.

  1998cites this paper
• Negative Symptoms in Schizophrenia: Neurobiological Models and Treatment Response

  1998cites this paper
• The dopamine hypothesis of schizophrenia: current status, future prospects.

  1997cites this paper